|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
US4741900A
(en)
|
1982-11-16 |
1988-05-03 |
Cytogen Corporation |
Antibody-metal ion complexes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
GB8430252D0
(en)
|
1984-11-30 |
1985-01-09 |
Beecham Group Plc |
Compounds
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
JP2703764B2
(ja)
|
1986-04-28 |
1998-01-26 |
シータス オンコロジー コーポレイション |
補体成分Ｃ５ａに対するモノクローナル抗体
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5256642A
(en)
|
1988-04-01 |
1993-10-26 |
The Johns Hopkins University |
Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
|
|
NZ230747A
(en)
|
1988-09-30 |
1992-05-26 |
Bror Morein |
Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5166322A
(en)
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
US5244800A
(en)
|
1990-04-27 |
1993-09-14 |
The Uab Research Foundation |
Crystals of human complement factor d that are triclinic
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
AU2147192A
(en)
|
1991-06-28 |
1993-01-25 |
Genentech Inc. |
Method of stimulating immune response using growth hormone
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
US5456909A
(en)
|
1992-08-07 |
1995-10-10 |
T Cell Sciences, Inc. |
Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
|
|
DK0656789T3
(da)
|
1992-08-21 |
1998-08-24 |
Genentech Inc |
Fremgangsmåde til behandling af en LFA-1-medieretforstyrrelse.
|
|
JPH08506095A
(ja)
|
1992-11-25 |
1996-07-02 |
アムジェン ボールダー インコーポレイテッド |
改変インシュリン様成長因子
|
|
US5861156A
(en)
|
1993-01-08 |
1999-01-19 |
Creative Biomolecules |
Methods of delivering agents to target cells
|
|
EP0708655A1
(en)
|
1993-04-07 |
1996-05-01 |
Amgen Boulder Inc. |
Methods of using insulin-like growth factor binding proteins
|
|
US5856300A
(en)
|
1994-05-12 |
1999-01-05 |
T Cell Sciences, Inc. |
Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions
|
|
US5679546A
(en)
|
1993-09-24 |
1997-10-21 |
Cytomed, Inc. |
Chimeric proteins which block complement activation
|
|
US5627264A
(en)
|
1994-03-03 |
1997-05-06 |
Alexion Pharmaceuticals, Inc. |
Chimeric complement inhibitor proteins
|
|
DE69533921T2
(de)
|
1994-03-23 |
2005-12-01 |
Alexion Pharmaceuticals, Inc., New Haven |
Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
|
|
US5534615A
(en)
|
1994-04-25 |
1996-07-09 |
Genentech, Inc. |
Cardiac hypertrophy factor and uses therefor
|
|
US5919623A
(en)
|
1994-04-27 |
1999-07-06 |
St. James's And Seacroft University Hospitals Nhs Trust |
Nucleic acid mutation assays
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US5679345A
(en)
|
1994-06-02 |
1997-10-21 |
The Johns Hopkins University |
Method for preventing complement-dependent rejection of organ or tissue transplants
|
|
US5897475A
(en)
|
1994-10-05 |
1999-04-27 |
Antex Biologics, Inc. |
Vaccines comprising enhanced antigenic helicobacter spp.
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
JP3628333B2
(ja)
|
1995-09-21 |
2005-03-09 |
ジェネンテック インコーポレーテッド |
ヒト成長ホルモン変異体
|
|
WO2000036102A2
(en)
|
1998-12-16 |
2000-06-22 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
WO2002008284A2
(en)
|
2000-07-20 |
2002-01-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
WO1999040100A1
(en)
|
1998-02-09 |
1999-08-12 |
Human Genome Sciences, Inc. |
45 human secreted proteins
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US6472520B2
(en)
|
1997-03-21 |
2002-10-29 |
The Trustees Of Columbia University In The City Of New York |
Rat PEG-3 promoter
|
|
KR100870353B1
(ko)
|
1997-04-07 |
2008-11-25 |
제넨테크, 인크. |
항-ｖｅｇｆ 항체
|
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
|
IL133974A0
(en)
|
1997-07-14 |
2001-04-30 |
Bolder Biotechnology Inc |
Derivatives of growth hormone and related proteins
|
|
US6410708B1
(en)
|
1997-11-21 |
2002-06-25 |
Genentech, Inc. |
Nucleic acids encoding A-33 related antigen polypeptides
|
|
DE69835524T2
(de)
|
1997-08-26 |
2007-04-05 |
Amgen Fremont Inc. |
Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg
|
|
US8007798B2
(en)
|
1997-11-21 |
2011-08-30 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
US7282565B2
(en)
|
1998-03-20 |
2007-10-16 |
Genentech, Inc. |
PRO362 polypeptides
|
|
US7419663B2
(en)
|
1998-03-20 |
2008-09-02 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
|
ATE410512T1
(de)
|
1997-11-21 |
2008-10-15 |
Genentech Inc |
Plättchen-spezifische antigene und deren pharmazeutische verwendung
|
|
US7005504B2
(en)
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
CN101298481A
(zh)
|
1998-02-20 |
2008-11-05 |
吉宁特有限公司 |
补体活化的抑制剂
|
|
US6956107B2
(en)
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
EP1490386B1
(en)
|
1998-03-10 |
2008-08-13 |
Genentech, Inc. |
Novel polypeptide and nucleic acids encoding the same
|
|
CA2340794A1
(en)
|
1998-08-27 |
2000-03-09 |
Incyte Pharmaceuticals, Inc. |
Protein transport-associated molecules
|
|
US6376653B1
(en)
|
1998-09-28 |
2002-04-23 |
Smithkline Beecham Plc |
Tie2 antagonist antibodies
|
|
ES2327785T3
(es)
|
1998-12-22 |
2009-11-03 |
Genentech, Inc. |
Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
CA2362427A1
(en)
|
1999-03-08 |
2000-09-14 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
EE05497B1
(et)
|
1999-03-11 |
2011-12-15 |
Rmf Dictagene S.A. |
Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
|
|
US6642353B1
(en)
|
1999-03-17 |
2003-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Peptide ligands for the erythropoietin receptor
|
|
AU2883900A
(en)
|
1999-07-07 |
2001-01-30 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1234030A4
(en)
|
1999-11-19 |
2003-05-07 |
Human Genome Sciences Inc |
18 HUMAN SECRETED PROTEINS
|
|
CA2491610A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP1253946A2
(en)
|
2000-02-10 |
2002-11-06 |
Alexion Pharmaceuticals, Inc. |
Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof
|
|
US6821775B1
(en)
|
2000-02-11 |
2004-11-23 |
Genvec, Inc. |
Viral vector encoding pigment epithelium-derived factor
|
|
US6998468B2
(en)
|
2000-03-23 |
2006-02-14 |
Tanox, Inc. |
Anti-C2/C2a inhibitors of complement activation
|
|
WO2001084149A2
(en)
|
2000-04-29 |
2001-11-08 |
University Of Iowa Research Foundation |
Diagnostics and therapeutics for macular degeneration-related disorders
|
|
EP1309620A2
(en)
|
2000-06-23 |
2003-05-14 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
US6534058B2
(en)
|
2000-10-10 |
2003-03-18 |
Tanox, Inc. |
Anti-C5 monoclonal antibodies
|
|
PT1324776E
(pt)
|
2000-10-12 |
2009-12-23 |
Genentech Inc |
Formulações de proteína concentradas de viscosidade reduzida
|
|
EE200300179A
(et)
|
2000-10-13 |
2003-08-15 |
Biogen, Inc. |
Humaniseeritud LT-ß-R-i vastased antikehad
|
|
JP4731793B2
(ja)
|
2000-12-28 |
2011-07-27 |
アルセア テクノロジーズ インコーポレイテッド |
抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法
|
|
US20040077575A1
(en)
|
2002-01-11 |
2004-04-22 |
Giordano Giovan Giacomo |
Inhibition of pathological angiogenesis in vivo
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
ES2283594T5
(es)
|
2001-08-17 |
2016-03-15 |
Genentech, Inc. |
Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
|
|
CA2461292A1
(en)
|
2001-10-02 |
2003-04-10 |
Genentech, Inc. |
Apo-2 ligand variants and uses thereof
|
|
JP4574350B2
(ja)
|
2002-06-24 |
2010-11-04 |
ジェネンテック， インコーポレイテッド |
Ａｐｏ−２リガンド／ｔｒａｉｌ変異体とその使用法
|
|
WO2004032828A2
(en)
|
2002-07-31 |
2004-04-22 |
Seattle Genetics, Inc. |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
TWI323265B
(en)
|
2002-08-06 |
2010-04-11 |
Glaxo Group Ltd |
Antibodies
|
|
AU2003258714A1
(en)
|
2002-09-06 |
2004-03-29 |
Cytos Biotechnology Ag |
Immune modulatory compounds and methods
|
|
US7816497B2
(en)
|
2002-10-30 |
2010-10-19 |
University Of Kentucky |
Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration
|
|
AU2003301813A1
(en)
|
2002-10-30 |
2004-06-07 |
University Of Kentucky Research Foundation |
Methods and animal model for analyzing age-related macular degeneration
|
|
AU2004216176B2
(en)
|
2003-02-21 |
2008-04-03 |
Genentech, Inc. |
Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
|
|
RU2232991C1
(ru)
|
2003-04-09 |
2004-07-20 |
Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" |
Способ определения функциональной активности фактора d комплемента человека
|
|
KR100512483B1
(ko)
|
2003-05-07 |
2005-09-05 |
선바이오(주) |
신규한 폴리에틸렌글리콜-말레이미드 유도체의 합성방법
|
|
US7709610B2
(en)
|
2003-05-08 |
2010-05-04 |
Facet Biotech Corporation |
Therapeutic use of anti-CS1 antibodies
|
|
EP2267028A3
(en)
|
2003-06-30 |
2011-07-27 |
Domantis Limited |
Dual specific single domain antibodies (dAb) conjugated to PEG
|
|
SI1639011T1
(sl)
|
2003-06-30 |
2009-04-30 |
Domantis Ltd |
Pegilirana protitelesa z enojno domeno (dAb)
|
|
WO2005014849A2
(en)
|
2003-07-03 |
2005-02-17 |
Euro-Celtique, S.A. |
Genes associated with responses to neuropathic pain
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
WO2005025509A2
(en)
|
2003-09-11 |
2005-03-24 |
Board Of Regents, The University Of Texas System |
Methods and materials for treating autoimmune diseases and conditions
|
|
US20050169921A1
(en)
|
2004-02-03 |
2005-08-04 |
Leonard Bell |
Method of treating hemolytic disease
|
|
US20090087854A1
(en)
|
2007-09-27 |
2009-04-02 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7127355B2
(en)
|
2004-03-05 |
2006-10-24 |
Perlegen Sciences, Inc. |
Methods for genetic analysis
|
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
BRPI0518289A2
(pt)
|
2004-11-18 |
2008-11-11 |
Univ Yale |
mÉtodos e composiÇÕes para o tratamento de desordens oculares
|
|
WO2006071856A2
(en)
|
2004-12-23 |
2006-07-06 |
Glycofi, Inc. |
Immunoglobulins comprising predominantly a man5glcnac2 glycoform
|
|
US8916351B2
(en)
|
2005-01-04 |
2014-12-23 |
Hitachi Chemical Co., Ltd. |
Primer generation rolling circle amplification
|
|
CA2597411C
(en)
|
2005-02-14 |
2014-08-12 |
University Of Iowa Research Foundation |
Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
|
|
NZ565659A
(en)
|
2005-06-08 |
2010-03-26 |
Univ Pittsburgh |
Susceptibility genes for age-related maculopathy (ARM) on chromosome 10Q26
|
|
BRPI0617186A2
(pt)
|
2005-10-08 |
2011-07-19 |
Potentia Pharmaceuticals Inc |
uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste
|
|
HUE026423T2
(en)
|
2005-11-04 |
2016-05-30 |
Genentech Inc |
Use of complement biosynthetic pathway inhibitors for treating eye diseases
|
|
US20070190057A1
(en)
|
2006-01-23 |
2007-08-16 |
Jian Wu |
Methods for modulating mannose content of recombinant proteins
|
|
AR059066A1
(es)
|
2006-01-27 |
2008-03-12 |
Amgen Inc |
Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
|
|
US20080146501A1
(en)
|
2006-02-13 |
2008-06-19 |
University Of Iowa Research Foundation |
Protective complement proteins and age-related macular degeneration
|
|
US8097617B2
(en)
|
2006-03-31 |
2012-01-17 |
Novartis Ag |
Organic compounds
|
|
EP3753548A1
(en)
|
2006-06-16 |
2020-12-23 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
|
KR20090060453A
(ko)
*
|
2006-09-25 |
2009-06-12 |
메디뮨 엘엘씨 |
안정화된 항체 제제 및 그것의 용도
|
|
SI2097455T1
(sl)
|
2006-11-02 |
2015-03-31 |
Genentech, Inc. |
Humanizirana protitelesa proti faktorju tipa d
|
|
AU2008251801A1
(en)
|
2007-05-11 |
2008-11-20 |
The General Hospital Corporation |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
AR066660A1
(es)
|
2007-05-23 |
2009-09-02 |
Genentech Inc |
Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
|
|
AU2008252853B2
(en)
*
|
2007-05-24 |
2011-12-01 |
Ablynx N.V. |
Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
WO2009029587A2
(en)
|
2007-08-24 |
2009-03-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
CA2721503A1
(en)
|
2008-04-18 |
2009-12-03 |
Massachusetts General Hospital |
Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk
|
|
WO2009134709A2
(en)
|
2008-04-28 |
2009-11-05 |
Tufts Medical Center |
Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
CN101724144A
(zh)
|
2008-11-03 |
2010-06-09 |
北京键凯科技有限公司 |
新型的多臂聚乙二醇及其制备方法和应用
|
|
EP2356250A2
(en)
|
2008-11-05 |
2011-08-17 |
Genentech, Inc. |
Genetic polymorphisms in age-related macular degeneration
|
|
US20120115925A1
(en)
|
2008-12-23 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Allelic Variants Associated with Advanced Age-Related Macular Degeneration
|
|
WO2010078063A1
(en)
|
2009-01-02 |
2010-07-08 |
Alcon Research, Ltd. |
In-situ refillable ophthalmic implant
|
|
WO2010085542A2
(en)
|
2009-01-23 |
2010-07-29 |
Novartis Ag |
Biomarkers related to age-related macular degeneration (amd)
|
|
CN104887389B
(zh)
|
2009-01-29 |
2017-06-23 |
弗赛特影像4股份有限公司 |
后段给药
|
|
WO2010132459A2
(en)
|
2009-05-11 |
2010-11-18 |
Cleveland Clinic Foundation |
Biomarkers for assessment of age-related macular degeneration
|
|
ES2827845T3
(es)
|
2009-07-02 |
2021-05-24 |
Lanzatech New Zealand Ltd |
Proceso de producción de alcohol
|
|
CA2781595C
(en)
|
2009-07-10 |
2016-07-05 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating macular degeneration
|
|
US20120190578A1
(en)
|
2009-08-06 |
2012-07-26 |
Washington University |
Plasma Complement Components as Expression Markers for Age-Related Macular Degeneration and Related Phenotypes
|
|
NZ598567A
(en)
|
2009-08-12 |
2013-09-27 |
Pure Bioscience |
Formulations and methods employing anhydrous disinfectant
|
|
US20110165648A1
(en)
|
2009-11-04 |
2011-07-07 |
Menno Van Lookeren Campagne |
Co-crystal structure of factor D and anti-factor D antibody
|
|
PH12012500924A1
(en)
*
|
2009-11-19 |
2012-11-26 |
Merck Serono Sa |
Humanized antibodies against human il-22ra
|
|
MX2012006406A
(es)
|
2009-12-04 |
2012-07-25 |
Genentech Inc |
Anticuerpos multiespecificos, analogos de anticuerpo, composiciones y metodos.
|
|
CN102108119A
(zh)
|
2009-12-25 |
2011-06-29 |
天津键凯科技有限公司 |
多臂聚乙二醇衍生物及其与药物的结合物和凝胶
|
|
BR112013005116A2
(pt)
*
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
|
SG190078A1
(en)
|
2010-11-01 |
2013-06-28 |
Genentech Inc |
Predicting progression to advanced age-related macular degeneration using a polygenic score
|
|
AU2012239997A1
(en)
*
|
2011-04-07 |
2013-10-17 |
Amgen Inc. |
Novel EGFR binding proteins
|
|
JP6532678B2
(ja)
|
2011-10-14 |
2019-06-19 |
ジェネンテック， インコーポレイテッド |
抗ＨｔｒＡ１抗体及び使用方法
|
|
JP6051998B2
(ja)
|
2012-03-30 |
2016-12-27 |
日油株式会社 |
マルチアーム型ポリエチレングリコール誘導体、その中間体及び製造方法
|
|
NZ712903A
(en)
*
|
2013-03-18 |
2018-07-27 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
|
CA2920666A1
(en)
|
2013-08-12 |
2015-02-19 |
Genentech, Inc. |
Compositions and method for treating complement-associated conditions
|
|
KR20160052562A
(ko)
|
2013-09-06 |
2016-05-12 |
에프. 호프만-라 로슈 아게 |
항체 안정성의 개선 방법
|
|
AR099625A1
(es)
*
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
CR20160561A
(es)
*
|
2014-05-01 |
2017-05-03 |
Genentech Inc |
Variantes del anticuerpo anti-factor d y sus usos
|
|
US10654932B2
(en)
|
2015-10-30 |
2020-05-19 |
Genentech, Inc. |
Anti-factor D antibody variant conjugates and uses thereof
|
|
CA3003647A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody formulations
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
JP6911026B2
(ja)
|
2015-10-30 |
2021-07-28 |
ジェネンテック， インコーポレイテッド |
Ｄ因子活性及びｄ因子阻害剤の力価を測定する方法
|